Levi & Korsinsky Investigates Possible Securities Fraud by Corcept Therapeutics Incorporated (CORT)

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following a Complete Response Letter (CRL) from the FDA regarding its new drug application for relacorilant [1][2] - The FDA's decision was based on the need for additional evidence of effectiveness despite acknowledging previous trial results [2] - Following the announcement, Corcept's stock price experienced a significant drop of $31.42, or 44.76%, reaching a new 52-week low of $38.78 per share [2][3] Company Developments - The FDA's CRL was issued on December 31, 2025, denying approval for relacorilant as a treatment for hypertension secondary to hypercortisolism [1] - The stock price decline marks a significant downturn, with levels not seen since September 2024 [3] Legal Context - Levi & Korsinsky LLP has initiated an investigation into Corcept, indicating potential legal ramifications for the company and its investors [1][4] - The firm has a strong track record in securities litigation, having secured substantial recoveries for shareholders in the past [4]